CytomX Therapeutics upgraded by H.C. Wainwright with a new price target
$CTMX
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright upgraded CytomX Therapeutics from Neutral to Buy and set a new price target of $5.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/20/2026 | $10.00 | Buy | Guggenheim |
| 9/22/2025 | $6.00 | Overweight | Cantor Fitzgerald |
| 9/17/2025 | $3.50 | Overweight | Barclays |
| 7/31/2025 | $7.00 | Outperform | Oppenheimer |
| 5/15/2025 | $5.00 | Neutral → Buy | H.C. Wainwright |
| 4/14/2025 | $3.25 → $2.50 | Overweight | Piper Sandler |
| 5/28/2024 | $2.25 → $3.50 | Neutral → Overweight | Piper Sandler |
| 5/9/2024 | $8.00 | Neutral → Outperform | Wedbush |
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
3 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00
Cantor Fitzgerald initiated coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $6.00
Barclays resumed coverage of CytomX Therapeutics with a rating of Overweight and set a new price target of $3.50
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan ("Varseta-M") Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027 - - Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to present at 44th Annual JP Morgan Healthcare Conference on January 14th - SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announ
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in December. 8th Annual Evercore Healthcare ConferenceDate: Tuesday, December 2, 2025Fireside Chat: 1:45 p.m. ETLocation: Coral Gables, FL Piper Sandler 37th Annual Healthcare ConferenceDate: Thursday, December 4, 2025Fireside Chat: 1:00 p.m. ETLocation: New York, NY A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at www.cytomx.com. In addition, management will be availab
SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
144 - CytomX Therapeutics, Inc. (0001501989) (Subject)
8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan ("Varseta-M") Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H 2027 - - Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to present at 44th Annual JP Morgan Healthcare Conference on January 14th - SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announ
- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of ongoing Phase 1 combination study with KEYTRUDA® (pembrolizumab) in melanoma - - Company to host conference call today at 5 p.m. EST / 2 p.m. PST - SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced third quarter 2025 financial results and provided a business update. "CytomX continued to execute against its pipeline priorities this quarter,
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior t
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice President, Chief Business Officer. In this role, Ms. Lester will lead the Company's strategy and business development functions. "Rachael brings a wealth of experience in strategic planning and business development across the biopharmaceutical industry and joins CytomX at a time when our platform and pipeline are well positioned to deliver meaningful advances in the treatment of many cancers," said Sean McCarthy, D.Phil., president, chief executive offic
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors. "We are excited to welcome Zhen to our board," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "With his extensive experience and accomplishments in oncology, Zhen brings expertise that will help shape strategy across our multi-modality PROBODY® therapeutic pipeline as well as CytomX's continued growth an